3
Clinical Trials associated with SIF-001 / Not yet recruitingPhase 2IIT An Exploratory Study on Monoclonal Antibody (SIF001) for the Treatment of Treatment-Resistant Depression
Start Date15 Sep 2025 |
Sponsor / Collaborator- |
A Phase 1, Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIF001 in Healthy Subjects and in a Patient Cohort With Epilepsy
This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy
/ Not yet recruitingEarly Phase 1IIT Exploratory Pilot Study of Monoclonal Antibody (SIF001) for the Treatment of Drug-Resistant Epilepsy
100 Clinical Results associated with SIF-001
100 Translational Medicine associated with SIF-001
100 Patents (Medical) associated with SIF-001
100 Deals associated with SIF-001